Publications by authors named "Dana Abubaker"
Article Synopsis
- * Mutations in the BCR-ABL gene, like the Threonine 315 to Isoleucine change, can make leukemia cells resistant to standard treatments known as tyrosine kinase inhibitors (TKIs).
- * In a research study using fruit flies as a model, expressing both normal and mutated versions of the gene revealed significant impacts on immune cell behaviors and disruptions in important immune pathways, indicating the more severe consequences of the mutation that warrant further study.
Leukemia involves different types of blood cancers, which lead to significant mortality and morbidity. Murine models of leukemia have been instrumental in understanding the biology of the disease and identifying therapeutics. However, such models are time consuming and expensive in high throughput genetic and drug screening.
View Article and Find Full Text PDFChronic myeloid leukemia is caused by a balanced chromosomal translocation resulting in the formation of fusion gene encoding a constitutively active BCR-ABL1 tyrosine kinase, which activates multiple signal transduction pathways leading to malignant transformation. Standard treatment of chronic myeloid leukemia is based on tyrosine kinase inhibitors; however, some mutations have proven elusive particularly the T315I mutation. is an established model for human diseases including cancer.
View Article and Find Full Text PDF